• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

促甲状腺激素(TSH)在培养的甲状腺细胞以及用硫脲嘧啶喂养的大鼠甲状腺中上调血管生成因子胎盘生长因子(PlGF)、血管内皮生长因子(VEGF)及其受体(Flt-1、Flk-1/KDR),提示存在一种TSH依赖性旁分泌机制参与甲状腺肿的血管过度增生。

Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.

作者信息

Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati M G, Mauriello V, Bruni P, Lago C T, Fusco A, Persico M G

机构信息

Istituto Nazionale dei Tumori Fondazione Senatore Pascale, Naples, Italy.

出版信息

Oncogene. 1997 Nov 27;15(22):2687-98. doi: 10.1038/sj.onc.1201456.

DOI:10.1038/sj.onc.1201456
PMID:9400995
Abstract

Placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) represent two closely related angiogenic growth factors active as homodimers or heterodimers. Since goiters of the thyroid gland are extremely hypervascular, we investigated the expression of PlGF, VEGF and their receptors, Flt-1 and Flk-1/KDR, in a small panel of human goiters from patients with Graves's disease, in an animal model of thyroid goitrogenesis and in in vitro cultured thyroid cells. Here we report that the mRNA expression of PlGF, VEGF and their receptors is markedly enhanced in biopsies of goiters resected from Graves's patients. In vivo studies demonstrated that in the thyroid gland of thiouracil-fed rats, increased mRNA and protein expression of PIGF, VEGF, Flt-1 and Flk-1/KDR occurred subsequent to the rise in the serum thyroid stimulating hormone (TSH) levels and in parallel with thyroid capillary proliferation. In vitro studies confirmed the existence of such TSH-dependent paracrine communication between thyroid epithelial cells and endothelium since the conditioned medium collected from TSH-stimulated thyrocytes acquired mitogenic activity for human umbilical vein endothelial (HUVE) cells. Altogether, these data suggest that PlGF and VEGF, released by thyrocytes in response to the chronic activation of the TSH receptor pathway, may act through a paracrine mechanism on thyroid endothelium.

摘要

胎盘生长因子(PlGF)和血管内皮生长因子(VEGF)是两种密切相关的血管生成生长因子,以同二聚体或异二聚体形式发挥作用。由于甲状腺肿血管极其丰富,我们研究了PlGF、VEGF及其受体Flt-1和Flk-1/KDR在一小部分来自格雷夫斯病患者的人类甲状腺肿、甲状腺肿发生的动物模型以及体外培养的甲状腺细胞中的表达。在此我们报告,从格雷夫斯病患者切除的甲状腺肿活检组织中,PlGF、VEGF及其受体的mRNA表达显著增强。体内研究表明,在喂食硫脲的大鼠甲状腺中,血清促甲状腺激素(TSH)水平升高后,PIGF、VEGF、Flt-1和Flk-1/KDR的mRNA和蛋白表达增加,且与甲状腺毛细血管增殖同时发生。体外研究证实了甲状腺上皮细胞与内皮细胞之间存在这种TSH依赖性旁分泌通讯,因为从TSH刺激的甲状腺细胞收集的条件培养基对人脐静脉内皮(HUVE)细胞具有促有丝分裂活性。总之,这些数据表明,甲状腺细胞响应TSH受体途径的慢性激活而释放的PlGF和VEGF可能通过旁分泌机制作用于甲状腺内皮。

相似文献

1
Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.促甲状腺激素(TSH)在培养的甲状腺细胞以及用硫脲嘧啶喂养的大鼠甲状腺中上调血管生成因子胎盘生长因子(PlGF)、血管内皮生长因子(VEGF)及其受体(Flt-1、Flk-1/KDR),提示存在一种TSH依赖性旁分泌机制参与甲状腺肿的血管过度增生。
Oncogene. 1997 Nov 27;15(22):2687-98. doi: 10.1038/sj.onc.1201456.
2
Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.促甲状腺激素和格雷夫斯免疫球蛋白G对体外培养的人甲状腺滤泡中血管内皮生长因子mRNA表达以及体内大鼠甲状腺中flt mRNA表达的刺激作用。
J Clin Invest. 1995 Sep;96(3):1295-302. doi: 10.1172/JCI118164.
3
Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.血管内皮生长因子(VEGF)上调及胎盘生长因子(PlGF)下调与人类甲状腺肿瘤及细胞系中的恶性肿瘤相关。
Oncogene. 1995 Oct 19;11(8):1569-79.
4
Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.胎盘生长因子/血管内皮生长因子异二聚体。内皮细胞活性、肿瘤细胞表达以及与Flk-1/KDR的高亲和力结合。
J Biol Chem. 1996 Feb 9;271(6):3154-62. doi: 10.1074/jbc.271.6.3154.
5
Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.Flt-1而非KDR/Flk-1酪氨酸激酶是胎盘生长因子的受体,胎盘生长因子与血管内皮生长因子相关。
Cell Growth Differ. 1996 Feb;7(2):213-21.
6
Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.胎盘生长因子刺激丝裂原活化蛋白激酶和有丝分裂活性,但不刺激磷脂酶C-γ以及表达Flt 1的内皮细胞的迁移。
Oncogene. 1998 Jan 22;16(3):359-67. doi: 10.1038/sj.onc.1201545.
7
Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast.人离体滋养层细胞中的血管内皮生长因子、胎盘生长因子及其受体
Placenta. 1997 Nov;18(8):657-65. doi: 10.1016/s0143-4004(97)90007-2.
8
Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.利用一种针对血管内皮生长因子(VEGF)激酶受体(fms样酪氨酸激酶受体和含激酶插入结构域的受体)的双功能双抗体完全抑制VEGF活性。
Cancer Res. 2001 Oct 1;61(19):7002-8.
9
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.胎盘生长因子。在体内外增强血管内皮生长因子的生物活性,与Flt-1具有高亲和力结合,但与Flk-1/KDR无结合。
J Biol Chem. 1994 Oct 14;269(41):25646-54.
10
Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.细胞毒性治疗恢复过程中血管生成生长因子及其受体的肿瘤特异性调节
Clin Cancer Res. 2002 Apr;8(4):1213-22.

引用本文的文献

1
Histological Alterations in Hashimoto's Disease: A Case-Series Ultrastructural Study.桥本氏病的组织学改变:一项病例系列超微结构研究
Medicines (Basel). 2023 Sep 2;10(9):51. doi: 10.3390/medicines10090051.
2
Usefulness of Real-Time Quantitative Microvascular Ultrasonography for Differentiation of Graves' Disease from Destructive Thyroiditis in Thyrotoxic Patients.实时定量微血管超声在鉴别毒性甲状腺毒症患者的 Graves 病与破坏性甲状腺炎中的作用。
Endocrinol Metab (Seoul). 2022 Apr;37(2):323-332. doi: 10.3803/EnM.2022.1413. Epub 2022 Apr 13.
3
Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables.
血清中血管内皮生长因子及血管内皮生长因子受体-1水平与甲状腺结节的组织病理学和放射学变量的相关性
J Lab Physicians. 2019 Jan-Mar;11(1):51-57. doi: 10.4103/JLP.JLP_41_18.
4
VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis.VEGFR2 而非 VEGFR3 调控甲状腺滤泡旁单位在正常状态和致甲状腺肿原作用下的完整性和重塑。
EMBO Mol Med. 2017 Jun;9(6):750-769. doi: 10.15252/emmm.201607341.
5
A potential role of the GRO-α/CXCR2 system in Sjögren's syndrome: regulatory effects of pro-inflammatory cytokines.GRO-α/CXCR2系统在干燥综合征中的潜在作用:促炎细胞因子的调节作用
Histochem Cell Biol. 2013 Feb;139(2):371-9. doi: 10.1007/s00418-012-1035-z. Epub 2012 Oct 5.
6
PlGF: a multitasking cytokine with disease-restricted activity.PlGF:一种具有疾病特异性活性的多功能细胞因子。
Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a011056. doi: 10.1101/cshperspect.a011056.
7
Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer.分化型甲状腺癌患者血清血管内皮生长因子的变化及预后价值。
Med Princ Pract. 2013;22(1):24-8. doi: 10.1159/000340051. Epub 2012 Aug 8.
8
Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations.促血管生成因子表达增加及血管生成在甲状腺功能亢进腺瘤中的作用,有无 TSH 受体激活突变。
Endocrine. 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3. Epub 2012 Jul 20.
9
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.酪氨酸激酶抑制剂引起的甲状腺功能减退症:发病率、病因和治疗。
Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.
10
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.血管生成抑制剂治疗肾癌及其作用机制。
Invest New Drugs. 2012 Aug;30(4):1791-801. doi: 10.1007/s10637-011-9677-6. Epub 2011 May 15.